Theravance Biopharma Inc
TBPH11.355USD
+0.455+4.17%
Horário de mercado （ET）Cotações atrasadas em 15 min
567.76MValor de mercado
PerdaP/L TTM
Mais detalhes de Theravance Biopharma Inc Empresa
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension.
Informações da empresa
Código da empresaTBPH
Nome da EmpresaTheravance Biopharma Inc
Data de listagemMay 16, 2014
CEOMr. Rick E. Winningham
Número de funcionários97
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 16
EndereçoUgland House, South Church Street
CidadeGEORGE TOWN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísCayman Islands
Código postalKY1-1104
Telefone16508086000
Sitehttps://www.theravance.com/
Código da empresaTBPH
Data de listagemMay 16, 2014
CEOMr. Rick E. Winningham
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Rick E. Winningham
Mr. Rick E. Winningham
Chief Executive Officer, Director
Chief Executive Officer, Director
1.31M
-2.21%
Dr. Aine Miller
Dr. Aine Miller
Senior Vice President - Development and Head of Ireland Office
Senior Vice President - Development and Head of Ireland Office
214.99K
+0.34%
Mr. Brett A. Grimaud
Mr. Brett A. Grimaud
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
160.16K
-5.73%
Mr. Aziz Sawaf
Mr. Aziz Sawaf
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
142.13K
-6.17%
Mr. Eran Broshy
Mr. Eran Broshy
Independent Director
Independent Director
91.20K
+13.22%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
74.20K
+16.76%
Dr. Deepika R. Pakianathan, Ph.D.
Dr. Deepika R. Pakianathan, Ph.D.
Independent Director
Independent Director
58.06K
+22.46%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Chairman of the Board
Independent Chairman of the Board
42.14K
+33.82%
Mr. Jeremy T. Grant
Mr. Jeremy T. Grant
Independent Director
Independent Director
28.54K
+59.52%
Mr. Dean Jonathan (Dean) Mitchell
Mr. Dean Jonathan (Dean) Mitchell
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Rick E. Winningham
Mr. Rick E. Winningham
Chief Executive Officer, Director
Chief Executive Officer, Director
1.31M
-2.21%
Dr. Aine Miller
Dr. Aine Miller
Senior Vice President - Development and Head of Ireland Office
Senior Vice President - Development and Head of Ireland Office
214.99K
+0.34%
Mr. Brett A. Grimaud
Mr. Brett A. Grimaud
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
160.16K
-5.73%
Mr. Aziz Sawaf
Mr. Aziz Sawaf
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
142.13K
-6.17%
Mr. Eran Broshy
Mr. Eran Broshy
Independent Director
Independent Director
91.20K
+13.22%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
74.20K
+16.76%
Detalhamento da receita
Moeda: USDAtualizado em: dom, 6 de jul
Moeda: USDAtualizado em: dom, 6 de jul
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
U.S.
64.38M
0.00%
Europe
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Madison Avenue Partners LP
19.02%
Weiss Asset Management
14.91%
Newtyn Management, LLC
9.51%
BlackRock Institutional Trust Company, N.A.
6.07%
Irenic Capital Management LP
5.52%
Other
44.96%
Investidores
Investidores
Proporção
Madison Avenue Partners LP
19.02%
Weiss Asset Management
14.91%
Newtyn Management, LLC
9.51%
BlackRock Institutional Trust Company, N.A.
6.07%
Irenic Capital Management LP
5.52%
Other
44.96%
Tipos de investidores
Investidores
Proporção
Hedge Fund
59.93%
Investment Advisor
16.82%
Investment Advisor/Hedge Fund
11.60%
Individual Investor
4.71%
Research Firm
2.89%
Bank and Trust
0.23%
Pension Fund
0.19%
Venture Capital
0.04%
Insurance Company
0.03%
Other
3.56%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
288
48.24M
96.47%
-10.03M
2025Q1
306
49.02M
97.92%
-10.33M
2024Q4
307
49.22M
100.10%
-11.44M
2024Q3
311
50.46M
103.15%
-9.84M
2024Q2
312
51.86M
106.61%
-21.43M
2024Q1
304
56.26M
115.67%
-11.52M
2023Q4
301
56.96M
111.33%
-13.16M
2023Q3
314
59.36M
109.50%
-14.46M
2023Q2
331
61.03M
103.70%
-24.91M
2023Q1
329
68.16M
106.54%
-18.37M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Madison Avenue Partners LP
9.51M
19.02%
--
--
Mar 31, 2025
Weiss Asset Management
7.46M
14.91%
--
--
Mar 31, 2025
Newtyn Management, LLC
4.76M
9.51%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.04M
6.07%
-127.84K
-4.04%
Mar 31, 2025
Irenic Capital Management LP
2.76M
5.52%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.08M
4.16%
+77.48K
+3.87%
Mar 31, 2025
Park West Asset Management LLC
1.80M
3.61%
+11.26K
+0.63%
Mar 31, 2025
Winningham (Rick E)
1.31M
2.61%
-29.60K
-2.21%
Jun 23, 2025
Oasis Management Company Ltd.
1.12M
2.24%
+3.17K
+0.28%
Mar 31, 2025
State Street Global Advisors (US)
1.07M
2.13%
-155.69K
-12.74%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Virtus LifeSci Biotech Products ETF
2%
Invesco NASDAQ Future Gen 200 ETF
0.54%
ALPS Medical Breakthroughs ETF
0.37%
Global X Aging Population ETF
0.35%
iShares U.S. Pharmaceuticals ETF
0.2%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.15%
iShares Micro-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
Avantis US Small Cap Equity ETF
0.05%
Ver Mais
Virtus LifeSci Biotech Products ETF
Proporção2%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.54%
ALPS Medical Breakthroughs ETF
Proporção0.37%
Global X Aging Population ETF
Proporção0.35%
iShares U.S. Pharmaceuticals ETF
Proporção0.2%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proporção0.15%
iShares Micro-Cap ETF
Proporção0.09%
Invesco Nasdaq Biotechnology ETF
Proporção0.06%
ProShares Ultra Nasdaq Biotechnology
Proporção0.06%
Avantis US Small Cap Equity ETF
Proporção0.05%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
